1. Home
  2. MDWD vs TBRG Comparison

MDWD vs TBRG Comparison

Compare MDWD & TBRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • TBRG
  • Stock Information
  • Founded
  • MDWD 2000
  • TBRG 1979
  • Country
  • MDWD Israel
  • TBRG United States
  • Employees
  • MDWD N/A
  • TBRG N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • TBRG
  • Sector
  • MDWD Health Care
  • TBRG
  • Exchange
  • MDWD Nasdaq
  • TBRG NYSE
  • Market Cap
  • MDWD 184.8M
  • TBRG 271.5M
  • IPO Year
  • MDWD 2014
  • TBRG N/A
  • Fundamental
  • Price
  • MDWD $19.02
  • TBRG $21.27
  • Analyst Decision
  • MDWD Strong Buy
  • TBRG Buy
  • Analyst Count
  • MDWD 1
  • TBRG 3
  • Target Price
  • MDWD $25.00
  • TBRG $14.67
  • AVG Volume (30 Days)
  • MDWD 61.7K
  • TBRG 78.7K
  • Earning Date
  • MDWD 11-26-2024
  • TBRG 02-27-2025
  • Dividend Yield
  • MDWD N/A
  • TBRG N/A
  • EPS Growth
  • MDWD N/A
  • TBRG N/A
  • EPS
  • MDWD N/A
  • TBRG N/A
  • Revenue
  • MDWD $19,720,000.00
  • TBRG $337,674,000.00
  • Revenue This Year
  • MDWD $10.37
  • TBRG $1.02
  • Revenue Next Year
  • MDWD $26.36
  • TBRG $6.06
  • P/E Ratio
  • MDWD N/A
  • TBRG N/A
  • Revenue Growth
  • MDWD N/A
  • TBRG 0.26
  • 52 Week Low
  • MDWD $11.04
  • TBRG $7.55
  • 52 Week High
  • MDWD $24.00
  • TBRG $21.80
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 61.79
  • TBRG 74.93
  • Support Level
  • MDWD $15.80
  • TBRG $20.62
  • Resistance Level
  • MDWD $18.25
  • TBRG $21.80
  • Average True Range (ATR)
  • MDWD 0.88
  • TBRG 0.72
  • MACD
  • MDWD 0.07
  • TBRG 0.08
  • Stochastic Oscillator
  • MDWD 95.27
  • TBRG 85.87

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About TBRG TRUBRIDGE INC

TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.

Share on Social Networks: